StockData
Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc. (PHAT) shareholders

PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 4/30
$6.06−0.17 (-2.73%)

Close on Nov 13, 2026Market cap $492.63MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
88.7%
72M of 81M shares
Institutional holders
162
22 new, 32 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Medicxi Ventures Management (Jersey) Limited
Joint filing with Medicxi Growth I GP Limited (6.60%), Medicxi IV GP Limited (6.50%) and 2 more
7,464,57213.00%13G (passive) amendmentJan 24, 2024
James N. Topper
Joint filing with Patrick J. Heron (7.30%), Fhmls Ix, L.L.C. (7.20%) and 5 more
6,013,3277.40%13D (active) amendmentOct 29, 2026
BlackRock, Inc.4,378,6475.50%13G (passive)Jun 30, 2026
Millennium Group Management LLC
Joint filing with Millennium Management LLC (5.30%), Israel A. Englander (5.30%)
4,178,4115.30%13G (passive)Mar 6, 2026
Israel A. Englander
Joint filing with Millennium Management LLC (5.90%), Millennium Group Management LLC (5.90%) and 1 more
4,160,5155.90%13G (passive) amendmentAug 19, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of PHATValueChange% of portfolio
Frazier Life Sciences Management, L.P.12,466,48915.34%$135.26M–2.95%
Medicxi Ventures Management (Jersey) Ltd7,464,5729.18%$80.99M–45.65%
BlackRock, Inc.4,525,1295.57%$49.10M+463,1330.00%
Invesco Ltd.4,029,7314.96%$43.72M−292,3290.00%
Carlyle Group Inc.3,496,8084.30%$37.94M–0.38%
Millennium Management LLC3,375,8344.15%$36.63M−647,0750.01%
Vanguard Capital Management LLC2,656,9443.27%$28.83M+73,3080.00%
GW&K Investment Management, LLC2,166,8382.67%$23.51M+745,7290.18%
Franklin Resources Inc1,970,8282.42%$21.38M+976,3240.00%
NEA Management Company, LLC1,960,1692.41%$21.27M–1.34%
683 Capital Management, LLC1,850,0002.28%$20.07M–0.99%
Goldman Sachs Group Inc1,778,0322.19%$19.29M+1,151,8360.00%
State Street Corp1,586,3231.95%$17.21M+199,4330.00%
Catalys Pacific, LLC1,493,8541.84%$16.21M–7.06%
Nomura Asset Management International Inc.1,462,7381.80%$15.87M+257,3690.02%
Geode Capital Management, LLC1,315,6871.62%$14.28M−12,3580.00%
Wasatch Advisors LP1,307,2471.61%$14.18M−33,6690.09%
Ensign Peak Advisors, Inc1,051,9131.29%$11.41M−575,8930.02%
Propel Bio Management, LLC1,050,3581.29%$11.40M+209,0865.96%
Point72 Asset Management, L.P.1,022,1931.26%$11.09MNew0.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202616272M88.7%22 / 5950 / 328M5M
Q1 202617469M85.0%37 / 7540 / 3516M5M
Q4 202517362M76.2%50 / 4950 / 106M6M
Q3 202513362M76.8%27 / 4528 / 118M3M
Q2 202511758M70.8%17 / 4238 / 368M15M
Q1 202513764M78.8%25 / 4835 / 315M7M
Q4 202414467M82.0%36 / 5927 / 228M14M
Q3 202413373M89.5%30 / 5718 / 1021M3M
Q2 202411458M71.6%18 / 4821 / 176M4M
Q1 202411456M68.9%13 / 4134 / 169M7M
Q4 202311754M66.9%25 / 5022 / 1714M3M
Q3 202311044M53.8%15 / 4824 / 73M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

159 funds held PHAT in Q2 2026, 38% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of PHATValue% of fundAs of
Invesco Global Fund2,342,4512.88%$20.50M0.23%Jul 31, 2026
Vanguard Total Stock Market Index Fund2,007,6682.47%$21.78M0.00%Jun 30, 2026
iShares Russell 2000 ETF1,279,3191.57%$13.88M0.02%Jun 30, 2026
Nomura Small Cap Growth Fund988,5141.22%$10.73M0.92%Jun 30, 2026
Strategic Advisers U.S. Total Stock Fund966,2871.19%$9.27M0.01%May 31, 2026
Franklin Small Cap Growth Fund827,0681.02%$7.24M0.29%Jul 31, 2026
Wasatch Micro Cap Fund806,5580.99%$8.75M1.30%Jun 30, 2026
Vanguard Extended Market Index Fund586,6320.72%$6.36M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund536,0380.66%$4.69M0.01%Jul 31, 2026
Franklin Biotechnology Discovery Fund507,4250.62%$4.44M0.38%Jul 31, 2026
Wasatch Ultra Growth Fund461,8760.57%$5.01M1.09%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF419,7860.52%$4.55M1.06%Jun 30, 2026
iShares Biotechnology ETF401,4130.49%$4.36M0.05%Jun 30, 2026
Invesco V.I. Global Fund356,1950.44%$3.86M0.28%Jun 30, 2026
JNL/Invesco Global Growth Fund337,3760.42%$3.75M0.32%Mar 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Steven L. BastaPresident and CEO, Director373,3150.46%Feb 12, 2026
Terrie CurranPresident and Chief Executive, Director364,3050.45%Mar 3, 2025
Sanjeev NarulaChief Financial & Bus. Officer215,8410.27%Oct 8, 2026
Robert Charles BreedlovePrincipal Accounting Officer67,6570.08%Sep 8, 2026
Anne Marie CookChief Legal Off. & Corp. Sec.88,6600.11%Feb 12, 2026
Molly HendersonCFO and CBO91,7790.11%Apr 8, 2025
Azmi NabulsiChief Operating Officer1,101,8691.36%Mar 3, 2025
Asit ParikhDirector172,6220.21%May 27, 2026
Mark StenhouseDirector54,1220.07%May 21, 2026
Heidi FieldsDirector54,1220.07%May 21, 2026
Michael F. ColaDirector63,9200.08%May 21, 2026
James N. TopperDirector, 10% owner5,957,4497.33%May 21, 2026
Theodore R. SchroederDirector45,1220.06%May 21, 2026
Frank KarbeDirector91,6220.11%May 21, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Sanjeev Narula
Chief Financial & Bus. Officer
Oct 6, 2026Tax withholding−13,485$6.78$91.43K214,718
Robert Charles Breedlove
Principal Accounting Officer
Sep 3, 2026Tax withholding−460$9.05$4.16K59,465
Robert Charles Breedlove
Principal Accounting Officer
Jul 14, 2026Tax withholding−1,555$11.04$17.17K59,925
Asit Parikh
Director
May 22, 2026Gift−28,000––24,122
Asit Parikh
Director
May 22, 2026Gift+28,000––148,500
Asit Parikh
Director
May 20, 2026Option exercise+17,500$4.95$86.63K52,122
Frank Karbe
Director
May 19, 2026Award+24,122––91,622
Theodore R. Schroeder
Director
May 19, 2026Award+24,122––45,122
Mark Stenhouse
Director
May 19, 2026Award+24,122––54,122
James N. Topper
Director, 10% owner
May 19, 2026Award+24,122––66,718
Asit Parikh
Director
May 19, 2026Award+24,122––34,622
Heidi Fields
Director
May 19, 2026Award+24,122––54,122
Michael F. Cola
Director
May 19, 2026Award+24,122––63,920
Asit Parikh
Director
Mar 10, 2026Gift−40,000––10,500
Asit Parikh
Director
Mar 10, 2026Gift+40,000––120,500
Robert Charles Breedlove
Principal Accounting Officer
Feb 27, 2026Tax withholding−414$12.56$5.20K61,480
Robert Charles Breedlove
Principal Accounting Officer
Feb 27, 2026Tax withholding−964$12.56$12.11K61,894
Robert Charles Breedlove
Principal Accounting Officer
Feb 27, 2026Award+2,790––62,858
Robert Charles Breedlove
Principal Accounting Officer
Feb 27, 2026Award+13,000––60,068
Steven L. Basta
President and CEO, Director
Feb 10, 2026Tax withholding−6,277$12.82$80.47K373,315
Steven L. Basta
President and CEO, Director
Feb 10, 2026Award+12,362––379,592
Anne Marie Cook
Chief Legal Off. & Corp. Sec.
Feb 10, 2026Tax withholding−1,535$12.82$19.68K88,660
Anne Marie Cook
Chief Legal Off. & Corp. Sec.
Feb 10, 2026Award+3,461––90,195
Asit Parikh
Director
Jan 23, 2026Gift+80,500––80,500
Asit Parikh
Director
Jan 23, 2026Gift−80,500––50,500
Robert Charles Breedlove
Principal Accounting Officer
Jan 21, 2026Tax withholding−776$13.61$10.56K47,068
Asit Parikh
Director
Jan 13, 2026Option exercise+8,750$10.30$90.13K131,000
Steven L. Basta
President and CEO, Director
Jan 2, 2026Award+251,034––364,820
Sanjeev Narula
Chief Financial & Bus. Officer
Jan 2, 2026Award+82,715––226,715
Anne Marie Cook
Chief Legal Off. & Corp. Sec.
Jan 2, 2026Award+75,345––85,012
Asit Parikh
Director
Dec 19, 2025Option exercise+8,750$10.30$90.13K122,250
Robert Charles Breedlove
Principal Accounting Officer
Dec 18, 2025Tax withholding−230$16.28$3.74K47,844
Anne Marie Cook
Chief Legal Off. & Corp. Sec.
Dec 17, 2025Award+17,370––17,370
Anne Marie Cook
Chief Legal Off. & Corp. Sec.
Dec 17, 2025Tax withholding−7,703$15.36$118.32K9,667
Steven L. Basta
President and CEO, Director
Dec 17, 2025Award+62,038––145,288
Steven L. Basta
President and CEO, Director
Dec 17, 2025Tax withholding−31,502$15.36$483.87K113,786
Steven L. Basta
President and CEO, Director
Nov 28, 2025Option exercise+90,000––131,625
Steven L. Basta
President and CEO, Director
Nov 28, 2025Tax withholding−48,375$15.62$755.62K83,250
Robert Charles Breedlove
Principal Accounting Officer
Nov 3, 2025Sale−524$13.51$7.08K47,407
Sanjeev Narula
Chief Financial & Bus. Officer
Oct 6, 2025Award+144,000––144,000
Steven L. Basta
President and CEO, Director
Sep 25, 2025Tax withholding−48,375$11.66$564.05K41,625
Steven L. Basta
President and CEO, Director
Sep 25, 2025Option exercise+90,000––90,000
Robert Charles Breedlove
Principal Accounting Officer
Sep 5, 2025Sale−461$12.09$5.57K47,931
Robert Charles Breedlove
Principal Accounting Officer
Jul 16, 2025Sale−1,692$8.36$14.15K48,392
Michael F. Cola
Director
Jun 3, 2025Award+10,500––39,798
Asit Parikh
Director
Jun 3, 2025Award+10,500––113,500
James N. Topper
Director, 10% owner
Jun 3, 2025Award+10,500––42,596
Heidi Fields
Director
Jun 3, 2025Award+10,500––30,000
Mark Stenhouse
Director
Jun 3, 2025Award+10,500––30,000
Frank Karbe
Director
Jun 3, 2025Award+10,500––67,500
James N. Topper
Director
May 21, 2025Buy+3,780$3.86$14.59K59,403
James N. Topper
Director
May 14, 2025Buy+6,300$3.32$20.92K55,623
James N. Topper
Director
May 13, 2025Buy+1,120$3.16$3.54K49,323
James N. Topper
Director
May 12, 2025Buy+12,601$3.04$38.31K48,203
James N. Topper
Director
May 9, 2025Buy+33,376$3.19$106.47K33,376
James N. Topper
Director
May 9, 2025Buy+2,226$3.62$8.06K35,602
Asit Parikh
Director
May 7, 2025Buy+5,000$2.40$12.00K95,500
Asit Parikh
Director
May 6, 2025Buy+5,000$2.60$13.00K90,500
Theodore R. Schroeder
Director
Apr 16, 2025Award+21,000––21,000
Molly Henderson
CFO and CBO
Apr 7, 2025Sale−3,678$4.55$16.73K89,868

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
12.89%
9M shares short
Days to cover
4.8
At 2M shares a day
Change since last report
-5.9%
From 10M shares
Short volume, 20 days
46.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Phathom Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 21,610 shares on Aug 25, 2026 over the last 90 days.

See a number that looks wrong?